Back to search

University of British Columbia

The modification of chimeric antigen receptor T cells to overcome immune suppression mediated by indoleamine 2,3-dioxygenase

Abstract

dc:description

Chimeric antigen receptor (CAR) T cells are regarded as a major breakthrough for treating hematological malignancies. Through expression of a receptor comprising an extracellular antigen-binding domain and intracellular stimulatory domains, CAR T cells can be re-directed to target cells expressing the antigen of choice where they are activated to proliferate and kill their targets. Despite representing a major advancement in the treatment of “liquid” tumours, the success of CAR T cells in solid tumours has been hampered in part by the immunosuppressive tumour microenvironment. Tumours form a complex network of cells and signaling molecules that promote tumour growth while suppressing the immune response. One of these mechanisms of immunosuppression is indoleamine 2,3-dioxyganse (IDO). IDO degrades tryptophan into a set of immunosuppressive metabolites called kynurenines. Through these actions, IDO activates suppressive immune cells while inhibiting anti-tumour immunity. In CAR T-cell therapy, IDO expression can suppress T-cell mediated killing and compromise treatment efficacy. The aim of this thesis is to enhance the ability of CAR T cells to contend with IDO-mediated immunosuppression in the tumour microenvironment. This engineering strategy involves the enzymatic degradation of suppressive kynurenines, which first requires knowledge of the specific kynurenines involved. Herein I show that of all kynurenines, kynurenine itself most strongly suppresses CAR T cells through the aryl hydrocarbon receptor, and I demonstrate the ability of T cells expressing kynureninase (KYNase) to degrade kynurenine in vitro. I outline the optimization of a model system to assess IDO-mediated immunosuppression of human CAR T cells in vivo, and use this system to evaluate the therapeutic effect of KYNase modification. I show that, while KYNase expression is ineffective at rescuing human CAR T-cell suppression in a subcutaneous tumour model in vivo, the modification of the CAR itself may influence its ability to withstand the immunosuppressive milieu produced by IDO. Furthermore, I identify the solvents used in in vitro assays as a possible confounding factor that may influence the interpretation of decades of research into kynurenine. This thesis contributes towards a better appreciation of the variability in IDO-mediated immunosuppression in vitro and in vivo, between species, and across diverse model systems.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Interdisciplinary Oncology
Grantor dc:publisher
University of British Columbia
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • May, Christopher Galen
Contributors dc:contributor
  • Holt, Robert A.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/87153

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

May, Christopher Galen. The modification of chimeric antigen receptor T cells to overcome immune suppression mediated by indoleamine 2,3-dioxygenase. doctoral thesis, University of British Columbia, 2023. http://hdl.handle.net/2429/87153